All In MedTech

Device Trial Radar · NCT04816604

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

74

Actual

Start

Apr 5, 2021

Primary completion

Sep 9, 2026

Study completion Sep 9, 2026

Sponsor

Lead sponsor
Gossamer Bio USA, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 25, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • GB002 (seralutinib)Drug

    Capsule containing GB002 (seralutinib)

  • Generic Dry Powder InhalerDevice

    Generic dry powder inhaler for GB002 (seralutinib) delivery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse EventsTime frame: From first dose of study drug up to 80 months or availability of commercial product

Locations

28 sites in 7 countries. Site status is shown where the registry gives one.

  • University of California, Davis Medical Center

    Sacramento, California

  • Medical Corporation

    Santa Barbara, California

  • Mayo Clinic

    Jacksonville, Florida

25 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.